Skip to main content
. Author manuscript; available in PMC: 2013 Dec 1.
Published in final edited form as: J Hum Genet. 2013 May 23;58(6):339–345. doi: 10.1038/jhg.2013.41

Figure 1.

Figure 1

Summary of results from the Pharmacogenomics of Anti-platelet Intervention (PAPI) Study. Panel A. Distribution of ADP-stimulated platelet aggregation before (upper panel) and after (lower panel) 7-days of clopidogrel exposure in 420 PAPI Study participants. Panel B. Genome-wide association analysis of clopidogrel response in the PAPI Study (upper panel) revealing genome-wide significant associations in the region of the CYP2C18-CYP2C19-CYP2C9-CYP2C8 cluster on chromosome 10 (lower panel). Panel C. Association of the loss of function CYP2C19*2 variant (rs4244285) with ADP-stimulated platelet aggregation post-clopidogrel (lower panel) but not pre-clopidogrel (upper panel) in PAPI Study participants. Figure adapted from Shuldiner41